Chargement en cours...
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature
Chemotherapy agents for patients with metastatic castration-resistant prostate cancer (mCRPC) include docetaxel and cabazitaxel. Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge. We, here, repor...
Enregistré dans:
| Publié dans: | Medicine (Baltimore) |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Wolters Kluwer Health
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998742/ https://ncbi.nlm.nih.gov/pubmed/27057826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002754 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|